7.08
-0.06(-0.84%)
Currency In USD
| Previous Close | 7.14 |
| Open | 7.01 |
| Day High | 7.3 |
| Day Low | 6.96 |
| 52-Week High | 16.94 |
| 52-Week Low | 1.8 |
| Volume | 68,246 |
| Average Volume | 331,323 |
| Market Cap | 65.51M |
| PE | -2.69 |
| EPS | -2.63 |
| Moving Average 50 Days | 8.72 |
| Moving Average 200 Days | 7.17 |
| Change | -0.06 |
If you invested $1000 in CervoMed Inc. (CRVO) 10 years ago, it would be worth $0.11 as of October 24, 2025 at a share price of $7.08. Whereas If you bought $1000 worth of CervoMed Inc. (CRVO) shares 5 years ago, it would be worth $113.73 as of October 24, 2025 at a share price of $7.08.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
CervoMed to Present at the Emerging Growth Conference
GlobeNewswire Inc.
Oct 20, 2025 12:00 PM GMT
BOSTON, Oct. 20, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Matthew Winton, Ph.D., Chief Comm
CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies
GlobeNewswire Inc.
Oct 08, 2025 11:00 AM GMT
Significant improvement relative to placebo on primary outcome measure, change in Clinical Dementia Rating Sum of Boxes (CDR-SB), demonstrated in a within-subject analysis in participants with low likelihood of having Alzheimer’s disease (AD) co-path
CervoMed Appoints Matthew Winton, Ph.D., as Chief Commercial and Business Officer
GlobeNewswire Inc.
Oct 07, 2025 12:00 PM GMT
Expanding executive leadership team to prepare for late-stage development, strategic organizational growth, and market readinessBOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing t